Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (131-140 of 198) with videos related to

Pageof 20
Sort By:
RMD Open|July 16, 2020
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II studyPhilip J Mease, Dafna D Gladman, Atul Deodhar, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Annals of the Rheumatic Diseases|September 30, 2019
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trialPhilip J Mease, Josef S Smolen, Frank Behrens, et al.
Arthritis Care & Research|July 18, 2013
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled studyPaul Emery, Roy M Fleischmann, Mittie K Doyle, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
The Journal of Rheumatology|November 3, 2005
Outcome measures in psoriatic arthritisDafna D Gladman, Philip J Mease, Gerald Krueger, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Therapeutic Advances in Musculoskeletal Disease|November 13, 2024
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studiesLars Erik Kristensen, William Tillett, Peter Nash, et al.
Pageof 20

Showing results (131-140 of 198) with videos related to

Sort By:
Pageof 20
RMD Open|July 16, 2020
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II studyPhilip J Mease, Dafna D Gladman, Atul Deodhar, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Annals of the Rheumatic Diseases|September 30, 2019
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trialPhilip J Mease, Josef S Smolen, Frank Behrens, et al.
Arthritis Care & Research|July 18, 2013
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled studyPaul Emery, Roy M Fleischmann, Mittie K Doyle, et al.
Clinical and Experimental Rheumatology|May 24, 2016
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis Research & Therapy|November 20, 2013
The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort studyVivek Thakkar, Wendy Stevens, David Prior, et al.
Arthritis and Rheumatism|June 3, 2008
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler, Frank Behrens, David Pittrow, et al.
The Journal of Rheumatology|November 3, 2005
Outcome measures in psoriatic arthritisDafna D Gladman, Philip J Mease, Gerald Krueger, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Therapeutic Advances in Musculoskeletal Disease|November 13, 2024
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studiesLars Erik Kristensen, William Tillett, Peter Nash, et al.
Pageof 20